window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 14, 2025

  • News
  • About Us
Contact Us

Patient Access

  • Artificial Intelligence,Clinical Development,Partnerships & Funding

    myTomorrows secures $29 million from Avego to expand global access to pre-approval treatments

    myTomorrows has raised $29 million from Avego to support its [...]

    November 11, 2025
  • Artificial Intelligence,Partnerships & Funding,Patient Centricity,Research & Development

    Veeva and OpenEvidence form long-term AI partnership to accelerate clinical trial access and drug discovery

    Veeva Systems and OpenEvidence have announced a long-term partnership to [...]

    October 17, 2025
  • Cell & Gene Therapy,Clinical Development,Pharmaceuticals and therapeutics,Supply Chain & Logistics

    Vitalant launches national service hubs to expand patient access to cell and gene therapies

    Vitalant has launched a national hub-and-spoke model to expand patient [...]

    October 6, 2025
  • Digital Health,Pharmaceuticals and therapeutics,Supply Chain & Logistics

    Gifthealth streamlines patient access with AI-driven pharmacy logistics and direct-to-patient model

    As supply chain pressures and rising drug costs challenge patients [...]

    September 26, 2025
  • Biologics & Biosimilars,Chronic diseases,Clinical Development,Clinical Trials,Global health,Market Access & Commercialization,Medical devices,Patient Centricity,Pharmaceuticals and therapeutics,Regulatory Affairs

    Terumo BCT expands access to rare disease therapies across Latin America

    Terumo Blood and Cell Technologies has announced regulatory approvals for [...]

    September 22, 2025
  • Cell & Gene Therapy,Global health,Partnerships & Funding,Pharmaceuticals and therapeutics

    Terumo BCT and PwC Belgium join forces to break barriers in access to advanced cell and gene therapies

    Terumo Blood and Cell Technologies (Terumo BCT), a medical technology [...]

    September 8, 2025
  • Global health,Market Access & Commercialization,Pharmaceuticals and therapeutics,Regulatory Affairs

    Pharmaceuticals and therapeutics: Lilly to raise drug prices in Europe as it cuts US patient costs

    Lilly has voiced strong support for the US administration’s goal [...]

    August 20, 2025
  • Clinical Trials,Data Management,Real world evidence,Regulatory Affairs

    Clinical trials: TransCelerate and FDA explore pragmatic trial designs to broaden patient access

    TransCelerate BioPharma and the US Food and Drug Administration (FDA) [...]

    August 20, 2025
  • Artificial Intelligence,CDMOs & Manufacturing,Cell & Gene Therapy,Partnerships & Funding

    Unlocking collaboration: How data sharing and digital innovation are shaping the future of cell and gene therapy manufacturing

    The case for smarter collaboration in CGT manufacturing  As the [...]

    July 1, 2025
  • Cell & Gene Therapy,Regulatory Affairs

    UK experts urge Government to appoint Minister for cell and gene therapies

    Commission sets out 25 policy recommendations to unlock access and [...]

    June 23, 2025
12Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top